The Big Short: Former Blackrock Fund Manager’s Big Pharma Vaccine Fraud Thesis in a Nutshell | KLIM
If you missed the January podcast, “Are Pfizer and Moderna the Next Enron?,”
former Blackrock fund manager Edward Dowd succinctly summarizes the reasoning behind his ‘big short’ Big Pharma investment case and adds some fascinating updates in this February 15th KLIM interview.
Dowd explains his initial hesitancy to take the Covid vaccine and the mushrooming “tells” that underpin his vax fraud thesis:
1) Long-term safety data on vaccines takes 7 - 10 years — you can’t “warp speed” safety information.
2) Pfizer failed the all-cause mortality endpoint in its clinical trial: more people died in the vaccinated group than in the placebo group. Typically, drugs don’t get approved if they fail that critical hurdle, it’s the “gold standard” in drug approval.
3) The FDA aggressively lobbied to hide the information it relied upon to license Pfizer’s COVID-19 vaccine,
asking a federal judge make the public wait until the year 2096, a total of 75 years, for the full set of data.
4) The widely respected British Medical Journal reported damning revelations from whistleblower Brook Jackson, who described how Pfizer ‘falsified data’ and manipulated its Covid vaccine clinical trials. For example, Jackson noted that the participants in her cohort had been unblinded after just 2 months. Unblinding is a clinical trial deal-breaker because knowing whether a person was vaccinated could influence the decision to test for Covid and report side effects. The supposed 95% vaccine efficacy was based on the fact that only 8 people in the vaccinated group got Covid versus 162 in the placebo group, a difference of just 154 (potentially untested unblinded) people.
5) In its Q4 earnings release, Pfizer quietly added new warning language: "…risks associated with... further information regarding the quality of pre-clinical, clinical or safety data, including by audit or inspection,” and highlighted "concerns about clinical data integrity..."
6) Six more life insurers have joined OneAmerica in reporting unheard of spikes in death claims among young working age individuals. In the second half of 2021 versus pre-pandemic 2019, deaths increased:
• +40% Q3 OneAmerica
• +36% Q4 Unum
• +57% Q4 Lincoln National
• +41% Q4 Prudential
• +21% Q4 RGA
• +32% Q4 Harford
• +268% Q3 Aegon, +56% Q4
7) Life insurers have started “reinsuring” their high face value individual policies at bargain prices. Dowd notes that while the economics look bad now, passing the death benefits hot potato to a reinsurance group may be a “genius” move in the long run. Aegon, for example, is predicting 300K excess US deaths in 2022, in part due to “indirect Covid” (translation: the jab).
